The guanine-quadruplex aptamer 93del inhibits HIV-1 replication ex vivo by interfering with viral entry, reverse transcription and integration

Antiviral Therapy

Volumn 16, Issue 3, 2011, Pages 383-394

  Faure Perraud, Aurélie ^a,b,c   Métifiot, Mathieu ^a,b,d   Reigadas, Sandrine ^a,b   Recordon Pinson, Patricia ^a,b   Parissi, Vincent ^a,b   Ventura, Michel ^a,b   Andréola, Marie Line ^a,b  

^a University Victor Segalen   (France)

^b Institut Fédératif De Recherches Pathologies Infectieuses IFR 66   (France)

^c UNIVERSITÉ DE LIMOGES   (France)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OLIGODEOXYNUCLEOTIDE 93DEL; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; GENETIC TRANSFECTION; HELA CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; VIRUS CELL INTERACTION; VIRUS DNA CELL DNA INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS PARTICLE;

APTAMERS, NUCLEOTIDE; DNA, VIRAL; G-QUADRUPLEXES; HELA CELLS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; VIRUS INTEGRATION; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 79959426343     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1756     Document Type: Article

References (40)

1. Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871. (Pubitemid 13080157)
2. Stolk LM, Luers JF. Increasing number of anti-HIV drugs but no definite cure. Review of anti-HIV drugs. Pharm World Sci 2004; 26:133-136. (Pubitemid 39012579)
3. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94:13193-13197. (Pubitemid 27518498)
4. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-1035. (Pubitemid 38269279)
5. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 1997; 71:5382-5390. (Pubitemid 27258214)
6. Emery S, Winston A. Raltegravir: a new choice in HIV and new chances for research. Lancet 2009; 374:764-766.
7. Brody EN, Gold L. Aptamers as therapeutic and diagnostic agents. J Biotechnol 2000; 74:5-13.
8. Gold L, Brown D, He Y, Shtatland T, Singer BS, Wu Y. From oligonucleotide shapes to genomic SELEX: novel biological regulatory loops. Proc Natl Acad Sci U S A 1997; 94:59-64. (Pubitemid 27031017)
9. Schneider DJ, Feigon J, Hostomsky Z, Gold L. Highaffinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry 1995; 34:9599-9610.
10. Pileur F, Andreola ML, Dausse E, et al. Selective inhibitory DNA aptamers of the human RNase H1. Nucleic Acids Res 2003; 31:5776-5788. (Pubitemid 37448480)
11. Kensch O, Connolly BA, Steinhoff HJ, McGregor A, Goody RS, Restle T. HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity. J Biol Chem 2000; 275:18271-18278. (Pubitemid 30414780)
12. DeStefano JJ, Nair GR. Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase. Oligonucleotides 2008; 18:133-144. (Pubitemid 352019747)
13. DeStefano JJ, Cristofaro JV. Selection of primer-template sequences that bind human immunodeficiency virus reverse transcriptase with high affinity. Nucleic Acids Res 2006; 34:130-139. (Pubitemid 43160039)
14. Joshi P, Prasad VR. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol 2002; 76:6545-6557. (Pubitemid 34633520)
15. Tuerk C, MacDougal-Waugh S. In vitro evolution of functional nucleic acids: high-affinity RNA ligands of HIV-1 proteins. Gene 1993; 137:33-39. (Pubitemid 24053729)
16. Marozzi A, Meneveri R, Giacca M, Gutierrez MI, Siccardi AG, Ginelli E. In vitro selection of HIV-1 TAR variants by the Tat protein. J Biotechnol 1998; 61:117-128. (Pubitemid 28269321)
17. Métifiot M, Leon O, Tarrago-Litvak L, Litvak S, Andreola ML. Targeting HIV-1 integrase with aptamers selected against the purified RNase H domain of HIV-1 RT. Biochimie 2005; 87:911-919. (Pubitemid 41297818)
18. Allen P, Worland S, Gold L. Isolation of high-affinity RNA ligands to HIV-1 integrase from a random pool. Virology 1995; 209:327-336.
19. Jing N, De Clercq E, Rando RF, et al. Stabilityactivity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. A basis for anti-HIV drug design. J Biol Chem 2000; 275:3421-3430. (Pubitemid 30083049)
20. Andreola ML, Pileur F, Calmels C, et al. DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry 2001; 40:10087-10094. (Pubitemid 32800116)
21. Phan AT, Kuryavyi V, Ma JB, Faure A, Andreola ML, Patel DJ. An interlocked dimeric parallel-stranded DNA quadruplex: a potent inhibitor of HIV-1 integrase. Proc Natl Acad Sci U S A 2005; 102:634-639. (Pubitemid 40282717)
22. de Soultrait VR, Lozach PY, Altmeyer R, Tarrago-Litvak L, Litvak S, Andreola ML. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J Mol Biol 2002; 324:195-203. (Pubitemid 35379020)
23. Ojwang JO, Buckheit RW, Pommier Y, et al. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995; 39:2426-2435.
24. Esté JA, Cabrera C, Schols D, et al. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol 1998; 53:340-345. (Pubitemid 28099745)
25. Métifiot M, Faure A, Guyonnet-Duperat V, et al. Cellular uptake of ODNs in HIV-1 human-infected cells: a role for viral particles in DNA delivery? Oligonucleotides 2007; 17:151-165. (Pubitemid 47124413)
26. Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, Clavel F. HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994; 241:651-662.
27. Ventura M, Tarrago-Litvak L, Dolle V, et al. Effect of nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions. Arch Virol 1999; 144:513-523. (Pubitemid 29172705)
28. Brussel A, Mathez D, Broche-Pierre S, et al. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS 2003; 17:645-652. (Pubitemid 36521070)
29. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 1988; 85:6132-6136.
30. D'Andrea G, Brisdelli F, Bozzi A. AZT: an old drug with new perspectives. Curr Clin Pharmacol 2008; 3:20-37. (Pubitemid 351210962)
31. Schultze P, Macaya RF, Feigon J. Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG). J Mol Biol 1994; 235:1532-1547. (Pubitemid 24150403)
32. Dollé V, Fan E, Nguyen CH, et al. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. J Med Chem 1995; 38:4679-4686.
33. Reigadas S, Andreola ML, Wittkop L, et al. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. J Antimicrob Chemother 2010; 65:434-437.
34. Neidle S. The structures of quadruplex nucleic acids and their drug complexes. Curr Opin Struct Biol 2009; 19:239-250.
35. Tan JH, Gu LQ, Wu JY. Design of selective G-quadruplex ligands as potential anticancer agents. Mini Rev Med Chem 2008; 8:1163-1178.
36. Patel DJ, Phan AT, Kuryavyi V. Human telomere, oncogenic promoter and 5′-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics. Nucleic Acids Res 2007; 35:7429-7455.
37. Wu Y. The second chance story of HIV-1 DNA: unintegrated? Not a problem! Retrovirology 2008; 5:61.
38. Zhu K, Dobard C, Chow SA. Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol 2004; 78:5045-5055. (Pubitemid 38581456)
39. Hehl EA, Joshi P, Kalpana GV, Prasad VR. Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J Virol 2004; 78:5056-5067. (Pubitemid 38581457)
40. Buckheit RW, Jr., Watson KM, Morrow KM, Ham AS. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res 2010; 85:142-158.